• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Request Free Sample ×
    ReportInfographic

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    GCC Neuropsychiatric Disorders Treatment Market

    ID: MRFR/HC/43516-HCR
    200 Pages
    Rahul Gotadki
    September 2025

    GCC Neuropsychiatric Disorders Treatment Market Research Report By Type (Degenerative Diseases, Neurotic Disorders, Psychosis, Others), By Application (Shock Treatment, Drug Treatment, Others) and By End User (Hospitals, Clinics, Research Centre’s, Others)- Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    GCC Neuropsychiatric Disorders Treatment Market Research Report - Forecast to 2035 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Table of Contents

    GCC Neuropsychiatric Disorders Treatment Market Summary

    The GCC Neuropsychiatric Disorders Treatment market is projected to grow significantly, reaching 15.1 USD Billion by 2035.

    Key Market Trends & Highlights

    GCC Neuropsychiatric Disorders Treatment Key Trends and Highlights

    • The market valuation is expected to increase from 4.71 USD Billion in 2024 to 15.1 USD Billion by 2035.
    • The compound annual growth rate (CAGR) is forecasted at 11.2 percent from 2025 to 2035.
    • This growth trajectory indicates a robust demand for innovative treatment options in the GCC region.
    • Growing adoption of advanced therapeutic technologies due to increasing awareness of mental health issues is a major market driver.

    Market Size & Forecast

    2024 Market Size 4.71 (USD Billion)
    2035 Market Size 15.1 (USD Billion)
    CAGR (2025-2035) 11.2%

    Major Players

    Roche, AstraZeneca, Johnson and Johnson, Sanofi, Otsuka Pharmaceutical, H. Lundbeck A/S, Novartis, Pfizer, Astellas Pharma, Teva Pharmaceutical Industries, Bristol Myers Squibb, GlaxoSmithKline, Merck and Co., AbbVie, Eli Lilly and Company

    GCC Neuropsychiatric Disorders Treatment Market Trends

    The GCC Neuropsychiatric Disorders Treatment Market is witnessing several key trends driven by increasing awareness and understanding of mental health issues. Governments in the region are focusing on enhancing mental health services, partly in response to rising cases of neuropsychiatric disorders. There is a notable emphasis on integrating mental health into primary healthcare systems, which is crucial for early diagnosis and treatment. Investments are being made to improve healthcare infrastructure, and initiatives have been launched to reduce the stigma around mental illness, encouraging people to seek help.

    The increasing prevalence of stress, anxiety, and depression, largely attributed to lifestyle changes and economic pressures, has propelled the demand for effective treatment options.

    There are new possibilities within the GCC region due to the implementation of new therapies and digital health technologies. The expansion of telemedicine is making it easier to access mental health services, especially in areas that have a wide range of cultures and populations. Private and public partnerships can also work together to create new access points for previously inaccessible therapies. Due to the gradual understanding of the importance of mental health, the GCC region is increasingly taking steps to improve mental health literacy, which helps create an environment where patients can seek treatment more easily.

    Recently, there has been a move towards more individualized approaches to medicine for neuropsychiatric disorders with more focus on treatment plans aimed at the particular patient. Mental health programs have also caught up to global expectations, which helps ensure that the region progresses toward newer treatment protocols. Now that more people appreciate mental wellness, there is a great opportunity for the GCC Neuropsychiatric Disorders Treatment Market to grow in supporting patients with the care that they need.

    GCC Neuropsychiatric Disorders Treatment Market Drivers

    Market Segment Insights

    Neuropsychiatric Disorders Treatment Market Type Insights

    The GCC Neuropsychiatric Disorders Treatment Market is witnessing comprehensive growth, driven largely by the diverse classifications under the Type segment. The region has seen a notable rise in the prevalence of various neuropsychiatric disorders, thus propelling key treatment modalities. Among these, degenerative diseases, such as Alzheimer's and Parkinson's, play a crucial role as they require long-term management and extensive care options due to their progressive nature. 

    Neurotic disorders, which encompass conditions such as anxiety and obsessive-compulsive disorder, significantly impact the quality of life and garner substantial attention from healthcare providers, leading to an increase in innovative therapies tailored to mitigate their effects. Psychotic disorders, including schizophrenia and bipolar disorder, not only affect individuals but also create a significant societal burden, necessitating continuous research and development of targeted treatments. The discourse around these disorders highlights the importance of early intervention and the need for accessible care systems throughout the GCC region.

     Furthermore, the "Others" category incorporates several less common but significant conditions that also require focused treatment approaches, often reflecting the unique sociocultural fabric of the GCC. With growing awareness and support from medical institutions, the GCC Neuropsychiatric Disorders Treatment Market segmentation presents opportunities for advancements in therapeutic interventions across all these types, illustrating the dynamic interplay between healthcare needs and treatment innovations. Overall, these segments are interconnected through the shared goal of improving patient outcomes. 

    The increasing investment in mental health from governments and private sectors in the GCC is indicative of a broader trend toward recognizing and addressing the complexities of neuropsychiatric disorders. Hospital networks and healthcare policies increasingly emphasize the necessity of comprehensive treatment plans, encapsulating medication, therapy, and community support to better serve those affected by these varied conditions in the region. 

    As the GCC population continues to grow and age, the demand for effective treatment solutions within this segmented market is poised to expand, paving the way for improved healthcare delivery systems that encompass a wide array of therapeutic needs.

    Neuropsychiatric Disorders Treatment Market Application Insights

    The GCC Neuropsychiatric Disorders Treatment Market shows a diverse range of applications, which is crucial for addressing the myriad needs associated with neuropsychiatric disorders. Among these methods, Shock Treatment and Drug Treatment stand out as primary approaches utilized across the region. Shock Treatment is particularly significant in treatment protocols for severe conditions, offering rapid results where traditional methods may falter. On the other hand, Drug Treatment remains prevalent because of its ability to provide long-term management and symptom control for various disorders.

    The presence of a growing population and increasing awareness surrounding mental health issues in GCC countries has driven demand for these applications. Alongside these, other innovative methods are emerging, further diversifying the treatment landscape. Market statistics indicate a shift toward integrated treatment plans that combine pharmacological and non-pharmacological strategies. Furthermore, with advancements in research and technology, opportunities for developing more effective treatments continue to arise, ensuring that the GCC region can cater to its increasing patient population effectively.

    Neuropsychiatric Disorders Treatment Market End User Insights

    The GCC Neuropsychiatric Disorders Treatment Market, especially in the End User segment, showcases a diversified landscape comprising Hospitals, Clinics, Research Centers, and Other facilities. Hospitals are critical in this ecosystem, as they typically provide comprehensive care and access to specialized services, making them a vital part of neuropsychiatric treatment. Clinics, with their focus on outpatient therapy and early diagnosis, address a significant portion of the patient population, facilitating timely interventions.

    Research Centers play a crucial role in advancing the understanding of neuropsychiatric disorders through clinical trials and studies, which contributes to the development of innovative treatment options.Additionally, Other facilities, such as rehabilitation centers and community health organizations, contribute to a supportive care continuum, offering specialized resources for individuals recovering from neuropsychiatric conditions. 

    The prominence of these End User segments reflects the growing recognition of mental health issues in the GCC region, driven by increasing prevalence rates, better awareness initiatives, and governmental supports aimed at improving mental health services. Each segment offers unique opportunities for growth, influenced by the rising demand for mental health services and advancements in therapeutic approaches.By focusing on enhancing infrastructure and professional training across all End User segments, the GCC can address the mental health needs of its population effectively.

    Get more detailed insights about GCC Neuropsychiatric Disorders Treatment Market Research Report - Forecast to 2035

    Request Free Sample

    Regional Insights

    Key Players and Competitive Insights

    The GCC Neuropsychiatric Disorders Treatment Market is characterized by a growing number of players investing in research and development to address the increasing prevalence of mental health disorders in the region. This rising awareness regarding mental health is prompting both local and international companies to develop innovative therapies and solutions. The competitive landscape is driven by the demand for effective treatments for conditions like depression, anxiety, bipolar disorder, and schizophrenia.

    In this evolving market environment, key players are leveraging strategic partnerships, mergers, and acquisitions to enhance their market presence, expand product portfolios, and ultimately capture a larger share of this dynamic market.Roche has established a significant foothold in the GCC Neuropsychiatric Disorders Treatment Market, primarily through its innovative treatment options and robust product pipeline focusing on neuropsychiatric conditions. 

    The company is recognized for its strong commitment to research and development, continually investing in groundbreaking studies and clinical trials aimed at discovering effective therapies. Roche's strengths lie not only in its well-established reputation but also in its capacity to deliver high-quality medications that have been proven effective in treating various neuropsychiatric disorders.

    Additionally, its strategic collaborations with local healthcare providers enhance its visibility and reach within the GCC region, allowing Roche to respond effectively to the nuanced needs of patients and healthcare systems.AstraZeneca also plays a crucial role in the GCC Neuropsychiatric Disorders Treatment Market by providing a range of therapeutic options that address various neuropsychiatric conditions. 

    The company’s strategic focus on neuroscience has enabled it to introduce key products designed for the treatment of mental health disorders, thereby reinforcing its market presence in the region. AstraZeneca's strengths include a robust research and development network that facilitates innovation and swift adaptation to emerging trends within the GCC. The company has engaged in mergers and acquisitions that bolster its capabilities and expand its therapeutic expertise within neuropsychiatry.

    In addition to its product offerings, AstraZeneca is committed to improving healthcare outcomes through collaboration with healthcare professionals and institutions, supporting mental health awareness campaigns, and advocating for better access to treatment options across the GCC.

    Key Companies in the GCC Neuropsychiatric Disorders Treatment Market market include

    Industry Developments

    The GCC Neuropsychiatric Disorders Treatment Market is experiencing notable developments, driven by increased awareness of mental health issues and a growing demand for effective treatments. Recently, in October 2023, Roche expanded its mental health portfolio in the GCC, focusing on innovative therapies for depression and anxiety disorders. Similarly, AstraZeneca launched a new campaign to further clinical trials for its antipsychotic medications within the region, aiming for better patient outcomes. 

    The market has also witnessed a surge in the valuation of companies due to escalating investments and advancements in research and development. For example, in June 2022, Pfizer reported a significant increase in revenue attributed to its psychiatric medication line, also contributing to overall market growth. 

    Additionally, the region’s health authorities have intensified efforts to reduce the stigma surrounding neuropsychiatric diseases, leading to higher patient engagement. Notably, in September 2023, Otsuka Pharmaceutical announced a partnership with H. Lundbeck A/S for mental health initiatives in the GCC, enhancing their outreach to treatment options. This collaboration reflects a strategic move within the market, anticipating an uplift in therapeutic availability and accessibility for patients across the Gulf Cooperation Council member states.

    Market Segmentation

    Neuropsychiatric Disorders Treatment Market Type Outlook

    • Degenerative Diseases
    • Neurotic Disorders
    • Psychosis
    • Others

    Neuropsychiatric Disorders Treatment Market End User Outlook

    • Hospitals
    • Clinics
    • Research Centre’s
    • Others

    Neuropsychiatric Disorders Treatment Market Application Outlook

    • Shock Treatment
    • Drug Treatment
    • Others

    Report Scope

    Report Attribute/Metric Source: Details
    MARKET SIZE 2023 4.74(USD Billion)
    MARKET SIZE 2024 5.22(USD Billion)
    MARKET SIZE 2035 15.06(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 10.107% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Billion
    KEY COMPANIES PROFILED Roche, AstraZeneca, Johnson and Johnson, Sanofi, Otsuka Pharmaceutical, Amgen, Novartis, Merck and Co, Pfizer, GSK, Teva Pharmaceutical Industries, BristolMyers Squibb, H. Lundbeck, AbbVie, Eli Lilly
    SEGMENTS COVERED Type, Application, End User
    KEY MARKET OPPORTUNITIES Aging population increasing treatment demand, Growing awareness of mental health, Advancements in neuropharmaceuticals, Telemedicine for therapy access, Integration of AI in diagnostics
    KEY MARKET DYNAMICS Increasing prevalence of disorders, Growing geriatric population, Advancements in treatment technology, Rising awareness and diagnosis, Expanding healthcare infrastructure
    COUNTRIES COVERED France

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Get In Touch
    Leave a Comment

    FAQs

    What is the expected market size of the France Neuropsychiatric Disorders Treatment Market in 2024?

    The France Neuropsychiatric Disorders Treatment Market is expected to be valued at 5.22 USD Billion in 2024.

    What is the projected market size in 2035 for the France Neuropsychiatric Disorders Treatment Market?

    By 2035, the France Neuropsychiatric Disorders Treatment Market is projected to reach a value of 15.06 USD Billion.

    What is the expected CAGR for the France Neuropsychiatric Disorders Treatment Market from 2025 to 2035?

    The expected CAGR for the France Neuropsychiatric Disorders Treatment Market from 2025 to 2035 is 10.107%.

    Which segment of the France Neuropsychiatric Disorders Treatment Market is projected to have the highest value in 2035?

    In 2035, the Degenerative Diseases segment is projected to have the highest value at 4.9 USD Billion.

    Who are the key players in the France Neuropsychiatric Disorders Treatment Market?

    Major players in the market include Roche, AstraZeneca, Johnson and Johnson, Sanofi, and Otsuka Pharmaceutical.

    What is the market value for the Neurotic Disorders segment in 2024?

    The Neurotic Disorders segment is valued at 1.4 USD Billion in 2024.

    What challenges does the France Neuropsychiatric Disorders Treatment Market currently face?

    The market currently faces challenges such as rising treatment costs and the need for innovative therapies.

    What is the market value for the Psychosis segment in 2035?

    The Psychosis segment is expected to reach a value of 3.0 USD Billion in 2035.

    What are the growth opportunities in the France Neuropsychiatric Disorders Treatment Market?

    There are growth opportunities in the development of new treatment modalities and personalized medicine.

    How significant is the Others segment expected to be by 2035?

    The Others segment is expected to grow to 3.16 USD Billion by 2035.

    1. EXECUTIVE
    2. SUMMARY
    3. Market Overview
    4. Key Findings
    5. Market Segmentation
    6. Competitive Landscape
    7. Challenges and Opportunities
    8. Future Outlook
    9. MARKET INTRODUCTION
    10. Definition
    11. Scope of the study
    12. Research Objective
    13. Assumption
    14. Limitations
    15. RESEARCH
    16. METHODOLOGY
    17. Overview
    18. Data
    19. Mining
    20. Secondary Research
    21. Primary
    22. Research
    23. Primary Interviews and Information Gathering
    24. Process
    25. Breakdown of Primary Respondents
    26. Forecasting
    27. Model
    28. Market Size Estimation
    29. Bottom-Up
    30. Approach
    31. Top-Down Approach
    32. Data
    33. Triangulation
    34. Validation
    35. MARKET
    36. DYNAMICS
    37. Overview
    38. Drivers
    39. Restraints
    40. Opportunities
    41. MARKET FACTOR ANALYSIS
    42. Value chain Analysis
    43. Porter's
    44. Five Forces Analysis
    45. Bargaining Power of Suppliers
    46. Bargaining
    47. Power of Buyers
    48. Threat of New Entrants
    49. Threat
    50. of Substitutes
    51. Intensity of Rivalry
    52. COVID-19
    53. Impact Analysis
    54. Market Impact Analysis
    55. Regional
    56. Impact
    57. Opportunity and Threat Analysis
    58. France
    59. Neuropsychiatric Disorders Treatment Market, BY Type (USD Billion)
    60. Degenerative
    61. Diseases
    62. Neurotic Disorders
    63. Psychosis
    64. Others
    65. France
    66. Neuropsychiatric Disorders Treatment Market, BY Application (USD Billion)
    67. Shock
    68. Treatment
    69. Drug Treatment
    70. Others
    71. France
    72. Neuropsychiatric Disorders Treatment Market, BY End User (USD Billion)
    73. Hospitals
    74. Clinics
    75. Research
    76. Centre’s
    77. Others
    78. Competitive Landscape
    79. Overview
    80. Competitive
    81. Analysis
    82. Market share Analysis
    83. Major
    84. Growth Strategy in the Neuropsychiatric Disorders Treatment Market
    85. Competitive
    86. Benchmarking
    87. Leading Players in Terms of Number of Developments
    88. in the Neuropsychiatric Disorders Treatment Market
    89. Key
    90. developments and growth strategies
    91. New Product Launch/Service
    92. Deployment
    93. Merger & Acquisitions
    94. Joint
    95. Ventures
    96. Major Players Financial Matrix
    97. Sales
    98. and Operating Income
    99. Major Players R&D Expenditure.
    100. Company
    101. Profiles
    102. Roche
    103. Financial
    104. Overview
    105. Products Offered
    106. Key
    107. Developments
    108. SWOT Analysis
    109. Key
    110. Strategies
    111. AstraZeneca
    112. Financial
    113. Overview
    114. Products Offered
    115. Key
    116. Developments
    117. SWOT Analysis
    118. Key
    119. Strategies
    120. Johnson and Johnson
    121. Financial
    122. Overview
    123. Products Offered
    124. Key
    125. Developments
    126. SWOT Analysis
    127. Key
    128. Strategies
    129. Sanofi
    130. Financial
    131. Overview
    132. Products Offered
    133. Key
    134. Developments
    135. SWOT Analysis
    136. Key
    137. Strategies
    138. Otsuka Pharmaceutical
    139. Financial
    140. Overview
    141. Products Offered
    142. Key
    143. Developments
    144. SWOT Analysis
    145. Key
    146. Strategies
    147. Amgen
    148. Financial
    149. Overview
    150. Products Offered
    151. Key
    152. Developments
    153. SWOT Analysis
    154. Key
    155. Strategies
    156. Novartis
    157. Financial
    158. Overview
    159. Products Offered
    160. Key
    161. Developments
    162. SWOT Analysis
    163. Key
    164. Strategies
    165. Merck and Co
    166. Financial
    167. Overview
    168. Products Offered
    169. Key
    170. Developments
    171. SWOT Analysis
    172. Key
    173. Strategies
    174. Pfizer
    175. Financial
    176. Overview
    177. Products Offered
    178. Key
    179. Developments
    180. SWOT Analysis
    181. Key
    182. Strategies
    183. GSK
    184. Financial
    185. Overview
    186. Products Offered
    187. Key
    188. Developments
    189. SWOT Analysis
    190. Key
    191. Strategies
    192. Teva Pharmaceutical Industries
    193. Financial
    194. Overview
    195. Products Offered
    196. Key
    197. Developments
    198. SWOT Analysis
    199. Key
    200. Strategies
    201. BristolMyers Squibb
    202. Financial
    203. Overview
    204. Products Offered
    205. Key
    206. Developments
    207. SWOT Analysis
    208. Key
    209. Strategies
    210. H. Lundbeck
    211. Financial
    212. Overview
    213. Products Offered
    214. Key
    215. Developments
    216. SWOT Analysis
    217. Key
    218. Strategies
    219. AbbVie
    220. Financial
    221. Overview
    222. Products Offered
    223. Key
    224. Developments
    225. SWOT Analysis
    226. Key
    227. Strategies
    228. Eli Lilly
    229. Financial
    230. Overview
    231. Products Offered
    232. Key
    233. Developments
    234. SWOT Analysis
    235. Key
    236. Strategies
    237. References
    238. Related
    239. Reports
    240. LIST
    241. OF ASSUMPTIONS
    242. France Neuropsychiatric Disorders Treatment
    243. Market SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2035 (USD Billions)
    244. France
    245. Neuropsychiatric Disorders Treatment Market SIZE ESTIMATES & FORECAST, BY APPLICATION,
    246. 2035 (USD Billions)
    247. France Neuropsychiatric Disorders
    248. Treatment Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    249. PRODUCT
    250. LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    251. ACQUISITION/PARTNERSHIP
    252. LIST
    253. Of figures
    254. MARKET SYNOPSIS
    255. FRANCE
    256. NEUROPSYCHIATRIC DISORDERS TREATMENT MARKET ANALYSIS BY TYPE
    257. FRANCE
    258. NEUROPSYCHIATRIC DISORDERS TREATMENT MARKET ANALYSIS BY APPLICATION
    259. FRANCE
    260. NEUROPSYCHIATRIC DISORDERS TREATMENT MARKET ANALYSIS BY END USER
    261. KEY
    262. BUYING CRITERIA OF NEUROPSYCHIATRIC DISORDERS TREATMENT MARKET
    263. RESEARCH
    264. PROCESS OF MRFR
    265. DRO ANALYSIS OF NEUROPSYCHIATRIC DISORDERS
    266. TREATMENT MARKET
    267. DRIVERS IMPACT ANALYSIS: NEUROPSYCHIATRIC
    268. DISORDERS TREATMENT MARKET
    269. RESTRAINTS IMPACT ANALYSIS:
    270. NEUROPSYCHIATRIC DISORDERS TREATMENT MARKET
    271. SUPPLY /
    272. VALUE CHAIN: NEUROPSYCHIATRIC DISORDERS TREATMENT MARKET
    273. NEUROPSYCHIATRIC
    274. DISORDERS TREATMENT MARKET, BY TYPE, 2024 (% SHARE)
    275. NEUROPSYCHIATRIC
    276. DISORDERS TREATMENT MARKET, BY TYPE, 2019 TO 2035 (USD Billions)
    277. NEUROPSYCHIATRIC
    278. DISORDERS TREATMENT MARKET, BY APPLICATION, 2024 (% SHARE)
    279. NEUROPSYCHIATRIC
    280. DISORDERS TREATMENT MARKET, BY APPLICATION, 2019 TO 2035 (USD Billions)
    281. NEUROPSYCHIATRIC
    282. DISORDERS TREATMENT MARKET, BY END USER, 2024 (% SHARE)
    283. NEUROPSYCHIATRIC
    284. DISORDERS TREATMENT MARKET, BY END USER, 2019 TO 2035 (USD Billions)
    285. BENCHMARKING
    286. OF MAJOR COMPETITORS

    GCC Neuropsychiatric Disorders Treatment Market Segmentation

    • Neuropsychiatric Disorders Treatment Market By Type (USD Billion, 2019-2035)

      • Degenerative Diseases
      • Neurotic Disorders
      • Psychosis
      • Others

     

    • Neuropsychiatric Disorders Treatment Market By Application (USD Billion, 2019-2035)

      • Shock Treatment
      • Drug Treatment
      • Others

     

    • Neuropsychiatric Disorders Treatment Market By End User (USD Billion, 2019-2035)

      • Hospitals
      • Clinics
      • Research Centre’s
      • Others
    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Related Reports

    No regional reports available for this market.

    No country-specific reports available for this market.

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials

    Global Magnesium Sulfate Market – Forecast till 2027